Aarhus Universitet

Running trials

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Source

• Not yet recruiting

  A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.

  2025-521269-28-00· Phase 2· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· Phase 3· Source

• Not yet recruiting

  Semaglutide Treatment in Type 1 Diabetes

  NCT06909006· Phase 3· Source

• Active, not recruiting

  HOPE in Diabetic Kidney Disease (HyperpOlarised PyruvatE in Diabetic Kidney Disease)

  2023-508824-36-00· Phase 2· Source

• Recruiting

  Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI

  2024-512491-35-00· Phase 2· Source

• Recruiting

  IMPROCAS - Improved Prediction of Ovarian Cancer Surgery

  2023-503398-39-00· Phase 2· Source

• Recruiting

  Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling

  NCT05431257· Phase 2· Source

• Recruiting

  A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).

  NCT04319367· Phase 2· Source

• Active, not recruiting

  A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT04408638· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

  NCT04623541· Phase 1/2· Source

• Recruiting

  MRI of Neurometabolic Impairment in ALS and TIA Using Hyperpolarized Pyruvate

  2024-516954-24-00· Phase 2· Source

• Recruiting

  MRI with hyperpolarized pyruvate in gliblastoma - a phase II study

  2024-515408-37-00· Phase 2· Source

• Active, not recruiting

  Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  NCT03772028· Phase 3· Source

• Recruiting

  SIOP RANDOMET 2017

  2023-508926-91-00· Phase 3· Source

• Completed

  Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis

  NCT03831776· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke2 recruiting
• Acute myeloid leukemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Childhood cancers1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glioblastoma1 recruiting
• HIV1 recruiting
• Lung cancer1 recruiting
• Macular degeneration1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)

  2024-514111-10-00· Phase 4· Source

• Recruiting

  Melanoma Metastasized to the Brain and Steroids

  NCT03563729· Phase 2· Source